Return to study ST002251 main page
MB Sample ID: SA216568
Local Sample ID: | FIT01-022-neg |
Subject ID: | SU002337 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Age Or Age Range: | 6-17 years |
Weight Or Weight Range: | Non-exacerbation-prone IQR: 30-68 kg; Exacerbation-prone IQR: 42-63 kg |
Height Or Height Range: | Non-exacerbation-prone IQR: 131-165 cm; Exacerbation-prone IQR: 140-163 cm |
Gender: | Male and female |
Human Race: | 18 white, 189 Black, 7 more than one race, 1 Asian |
Human Ethnicity: | 2 Hispanic, 113 Not Hispanic |
Human Medications: | 92 on high-dose inhaled corticosteroids; 94 on long-acting beta adrenergic receptor agonists; 111 on Montelukast |
Human Smoking Status: | 24 exposed to tobacco smoke |
Human Inclusion Criteria: | 1) current or historical evidence of >=12% reversibility in forced expiratory volume in one second (FEV1) relative to baseline after bronchodilator administration; 2) airway hyperresponsiveness to methacholine, with a provocative concentration of methacholine causing a 20% drop in FEV1 |
Human Exclusion Criteria: | 1) premature birth before 35 weeks of gestation; 2) other chronic airway disorders that could mimic asthma. |
Select appropriate tab below to view additional metadata details:
Subject:
Subject ID: | SU002337 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Age Or Age Range: | 6-17 years |
Weight Or Weight Range: | Non-exacerbation-prone IQR: 30-68 kg; Exacerbation-prone IQR: 42-63 kg |
Height Or Height Range: | Non-exacerbation-prone IQR: 131-165 cm; Exacerbation-prone IQR: 140-163 cm |
Gender: | Male and female |
Human Race: | 18 white, 189 Black, 7 more than one race, 1 Asian |
Human Ethnicity: | 2 Hispanic, 113 Not Hispanic |
Human Medications: | 92 on high-dose inhaled corticosteroids; 94 on long-acting beta adrenergic receptor agonists; 111 on Montelukast |
Human Smoking Status: | 24 exposed to tobacco smoke |
Human Inclusion Criteria: | 1) current or historical evidence of >=12% reversibility in forced expiratory volume in one second (FEV1) relative to baseline after bronchodilator administration; 2) airway hyperresponsiveness to methacholine, with a provocative concentration of methacholine causing a 20% drop in FEV1 |
Human Exclusion Criteria: | 1) premature birth before 35 weeks of gestation; 2) other chronic airway disorders that could mimic asthma. |
Factors:
Local Sample ID | MB Sample ID | Factor Level ID | Level Value | Factor Name |
---|---|---|---|---|
FIT01-022-neg | SA216568 | FL026196 | No | ThreeorMoreBursts |
FIT01-022-neg | SA216568 | FL026196 | No | ICShighdose |
FIT01-022-neg | SA216568 | FL026196 | SARP3 | Study |
FIT01-022-neg | SA216568 | FL026196 | 8.83 | AgeatEnrollment |
FIT01-022-neg | SA216568 | FL026196 | 5 | AsthmaDurationYears |
FIT01-022-neg | SA216568 | FL026196 | M | Sex |
FIT01-022-neg | SA216568 | FL026196 | Not Hispanic | Ethnicity |
FIT01-022-neg | SA216568 | FL026196 | Black | Race |
FIT01-022-neg | SA216568 | FL026196 | 127.8 | Height |
FIT01-022-neg | SA216568 | FL026196 | 27.8 | Weight |
FIT01-022-neg | SA216568 | FL026196 | 17.02 | BMI |
FIT01-022-neg | SA216568 | FL026196 | No | LABA |
FIT01-022-neg | SA216568 | FL026196 | No | Montelukast |
Collection:
Collection ID: | CO002330 |
Collection Summary: | Patients were not fasted prior to blood collection, but did withhold controller medication for 24 hours prior to blood collection. Blood was collected via venipuncture into EDTA-coated tubes. Plasma was isolated via centrifugation and stored at -80 *C. |
Sample Type: | Blood (plasma) |
Storage Conditions: | -80℃ |
Collection Vials: | EDTA-coated tubes |
Storage Vials: | Eppendorf tubes |
Collection Tube Temp: | Room temperature |
Additives: | EDTA |
Treatment:
Treatment ID: | TR002349 |
Treatment Summary: | Plasma samples were not treated with anything prior to metabolite extraction. |
Sample Preparation:
Sampleprep ID: | SP002343 |
Sampleprep Summary: | 50 uL of plasma was mixed with 200 uL of a 50:50 mixture of methanol and acetonitirile, vortexed, incubated on ice for 30 min, then centrifuged at 20,000 g for 10 min at 4 *C. 200 uL of the supernatant was collected for analysis. |
Extraction Method: | 50:50 methanol:acetonitrile for a 1:2:2 samples:methanol:acetonitrile final |
Extract Cleanup: | centrifuged at 20,000 g for 10 min at 4 *C |
Extract Storage: | -80℃ |
Combined analysis:
Analysis ID | AN003677 | AN003678 |
---|---|---|
Analysis type | MS | MS |
Chromatography type | HILIC | HILIC |
Chromatography system | Vanquish Horizon Binary ultrahigh performance liquid chromatography system | Vanquish Horizon Binary ultrahigh performance liquid chromatography system |
Column | SeQuant ZIC-HILIC | SeQuant ZIC-HILIC |
MS Type | ESI | ESI |
MS instrument type | Orbitrap | Orbitrap |
MS instrument name | Thermo Q Exactive HF hybrid Orbitrap | Thermo Q Exactive HF hybrid Orbitrap |
Ion Mode | POSITIVE | NEGATIVE |
Units | peak area | peak area |
Chromatography:
Chromatography ID: | CH002727 |
Chromatography Summary: | Equilibration time was 4 min at 90% B, with 3.5 min at 0.35 mL/min, then 0.5 min at 0.25 mL/min. After sample injection, a gradient ran from 90% to 20% B over 17.5 min at 0.25 mL/min, then flow was increased to 0.35 mL/min for 1 min and held at 20% B at 0.35 mL/min for 3.5 min. |
Instrument Name: | Vanquish Horizon Binary ultrahigh performance liquid chromatography system |
Column Name: | SeQuant ZIC-HILIC |
Column Pressure: | 15-180 bar |
Column Temperature: | 40 |
Flow Rate: | 0.25-0.35 mL/min |
Sample Injection: | 2 uL |
Solvent A: | 100% water; 0.1% formic acid |
Solvent B: | 100% acetonitrile; 0.1% formic acid |
Analytical Time: | 1.85-14.5 min |
Chromatography Type: | HILIC |
MS:
MS ID: | MS003428 |
Analysis ID: | AN003677 |
Instrument Name: | Thermo Q Exactive HF hybrid Orbitrap |
Instrument Type: | Orbitrap |
MS Type: | ESI |
MS Comments: | Data were processed using Compound Discoverer 3.2 (Thermo). Minimum peak intensity was 5E5 for positive mode. Retention times were aligned across runs, quality control (QC) pooled sample areas were normalized per metabolite using a cubic spline method, requiring <50% relative standard deviation after correction for compound retention. Missing values were gap-filled based on real peak detection and metabolites with max sample area <5-fold that of the blank were censored. |
Ion Mode: | POSITIVE |
Capillary Temperature: | 275 |
Ion Spray Voltage: | +3.5 kV |
Automatic Gain Control: | 1E6 |
MS ID: | MS003429 |
Analysis ID: | AN003678 |
Instrument Name: | Thermo Q Exactive HF hybrid Orbitrap |
Instrument Type: | Orbitrap |
MS Type: | ESI |
MS Comments: | Data were processed using Compound Discoverer 3.2 (Thermo). Minimum peak intensity was 2E5 for negative mode. Retention times were aligned across runs, quality control (QC) pooled sample areas were normalized per metabolite using a cubic spline method, requiring <50% relative standard deviation after correction for compound retention. Missing values were gap-filled based on real peak detection and metabolites with max sample area <5-fold that of the blank were censored. |
Ion Mode: | NEGATIVE |
Capillary Temperature: | 275 |
Ion Spray Voltage: | -2.75 kV |
Automatic Gain Control: | 1E6 |